ABSTRACT
INTRODUCTION R
ETROVIRAL VECTORS are one of the most popular gene delivery vehicles used in human gene therapy because of their ability to precisely integrate new sequences into the human genome (Fig. 1A) . Unfortunately, the fact that integration is only weakly influenced by primary sequence at the point of integration (Stevens and Griffith, 1996; Carteau et al., 1998; Holman and Coffin, 2005; Wu et al., 2005) means that integration can take place at many genomic locations, including sites that activate oncogenes and result in transformation. Such oncogene activation has now been seen during human gene therapy trials (Hacein-Bey-Abina et al., 2003a,b) . This has focused intense interest on the mechanisms driving integration site selection, with the long-term hope of increasing the safety of human gene therapy.
Previous studies in vitro with engineered retroviral integrases (INs) have shown that tethering via fused sequence-specific DNA-binding domains could constrain integration site selection. Combinations tested included human immunodeficiency virus (HIV) IN linked to the DNA-binding domain of phage repressor protein (R) (Bushman, 1994) , HIV IN linked to LexA (Goulaouic and Chow, 1996) , HIV IN linked to zinc finger proteins (Bushman and Miller, 1997; Tan et al., 2004) , and avian sarcoma-leukosis virus (ASLV) IN linked to LexA (Katz et al., 1996) . Each of these fusions programmed integration near the binding site for the linked DNA-binding domain in vitro.
In an important step, Tan et al. reported that such fusions in vivo can increase integration near the binding site for a fusion partner 10-fold (Tan et al., 2006) . However, most integration was still elsewhere in the genome and vector titer was reduced.
Here we investigate whether a protein-protein interaction between an IN protein and a tethering protein engineered to bind both IN and specific DNA sites can target integration, using an in vitro model.
The IN-binding protein lens epithelium-derived growth factor (LEDGF)/p75 has been implicated previously in binding tightly to HIV IN and targeting HIV integration, providing one of the reagents used in our study Maertens et al., 2003; Llano et al., 2004a,b; Turlure et al., 2004; Bushman et al., 2005; Ciuffi et al., 2005; Vandegraaff et al., 2006) . Although LEDGF/p75 binds HIV IN tightly, tests of HIV titer after infection of target cells depleted for LEDGF/p75 showed only modest effects on viral titer (Boese et al., 2004; Llano et al., 2004b; Vandegraaff et al., 2006; and A. Ciuffi and F.D. Bushman, unpublished data; but see Emiliani et al. [2005] FIG. 1. Early steps of HIV DNA integration, and diagram of the LEDGF/p75 domain structure. (A) The initial DNA-breaking and joining reactions that mediate retroviral DNA integration are carried out by the virus-encoded IN protein (Katzman et al., 1989; Craigie et al., 1990; Katz et al., 1990; Sherman and Fyfe, 1990; Bushman and Craigie, 1991) . IN first cleaves the ends of the viral DNA (terminal cleavage) and then joins the exposed 3Ј ends to target DNA on one strand at each host-virus DNA junction (strand transfer). The joining of the second DNA strand at each end and removal of the 5Ј overhang is probably carried out by the host cell enzymes that normally repair DNA gaps (Yoder and Bushman, 2000) . (B) The name LEDGF/p75 derives from early findings that (1) LEDGF/p75 was important in lens cells (hence "lens epithelium-derived growth factor") (Shinohara et al., 2002) and (2) acts as a transcriptional coactivator and was named for its molecular weight ("p75") (Ge et al., 1998) . The name notwithstanding, LEDGF/p75 is expressed in most cell types and not just lens cells (Ge et al., 1998) . IBD, integrin-binding domain; NLS, nuclear localization signal. and Vandekerckhove et al. [2006] for an opposing view), thus we have focused here on involvement of LEDGF/p75 in integration target site selection. One study supported a role for LEDGF/p75 in integration targeting in vivo . In human cells, HIV is known to favor integration in active transcription units (abbreviated TUs) (Schroder et al., 2002; Wu et al., 2003; Mitchell et al., 2004) . LEDGF/p75 was previously implicated in gene regulation (Ge et al., 1998) , making it attractive as a factor mediating HIV integration in active TUs. Three human cell lines were depleted for LEDGF/p75, using short hairpin RNAs (shRNAs) against LEDGF/p75, and more than 4000 HIV integration site sequences were determined in knockdown cells and controls. This revealed several effects on HIV integration site selection, including a significant reduction in the frequency of integration in TUs in the knockdown cells . These data supported the idea that LEDGF/p75 promoted HIV integration in transcription units by tethering integration complexes at these sites.
Here we used assays in vitro to investigate HIV integration targeting in the presence of fusion proteins composed of LEDGF/p75 linked to a sequence-specific DNA-binding domain. Initial studies showed that LEDGF/p75 bound DNA sequence nonspecifically and so did not contribute a confounding DNA-binding specificity of its own. We prepared and analyzed fusions of LEDGF/p75 to the R. We found that the R-LEDGF/p75 fusions directed favored integration in vitro near repressor-binding sites in integration target DNA, and that both IN-binding and DNA-binding functions were necessary for targeting. These studies in vitro support a tethering model for the mechanism of HIV integration targeting by LEDGF/p75, and demonstrate proof of concept for the idea that a protein-protein interaction can constrain integration site selection.
MATERIALS AND METHODS

DNA constructions
A plasmid encoding the N-terminal domain of the R alone or fused to the leucine zipper GCN4 (pFB257) (Hu et al., 1990; Bushman, 1994) was used as a cloning vector to introduce LEDGF/p75 or the integrase-binding domain (IBD), in frame, through NdeI and BamHI restriction sites. Primers (Table 1) containing the same restriction sites were used to amplify LEDGF/p75 or IBD by polymerase chain reaction (PCR), in order to obtain constructs encoding R 
(ND)-LEDGF, R(ND)-
IBD, R(ND)-GZ-LEDGF, and R(ND)-GZ-IBD.
tein-CBD-His and R(ND)-GZ-IBD-intein-CBD-His.
Immunity phenotypes of Escherichia coli containing R fusions were determined by cross-streak assay versus cI ( phages mutant in the cI gene, which encodes R) (Hendrix et al., 1983) .
Protein purification
Protein purification was performed essentially as in Diamond and Bushman (2005) . DNA plasmids encoding the various fusion proteins were transformed into E. coli BL21(DE3) and grown in 1 liter of SuperBroth (3.2% tryptone, 2% yeast extract, 0.5% NaCl, pH to 7.5 with 1 N NaOH. Add 100 ml/L of pH 7.5 phosphate buffer) to a minimal optical density of 0.5. Expression of the fusion proteins was induced by adding 500 M isopropyl-␤-D-1-thiogalactopyranoside (IPTG) for 3 hr. Bacteria were then pelleted, resuspended in Ni-lysis buffer (50 nM Na,K PO 4 : pH 8.0, 300 nM NaCl), supplemented with protease inhibitors (Sigma), and sonicated. Disrupted bacteria were pelleted and the clear supernatant was fractionated on Ni-NTA agarose (Qiagen, Valencia, CA) to achieve purification of histidine-tagged proteins. The eluate from the Ni-NTA column was applied to chitin beads (New England BioLabs) to allow further purification of the proteins of interest through the chitin-binding domain. Finally, the fusion proteins were released by intein-mediated selfcleavage induced with 50 mM dithiothreitol (DTT). The proteins were further concentrated on an SP Sepharose Fast Flow column (GE Healthcare Life Sciences, Piscataway, NJ) according to manufacturer's instructions and eluted with increasing NaCl concentrations. Purification of the viral IN was done similarly, but without the SP Sepharose step and in the presence of 10 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonic acid (CHAPS) throughout the purification procedure to prevent precipitation.
Assay of integration in vitro
In vitro integration assays were performed essentially as described in Bushman (1994) and Diamond and Bushman (2005) , with some modifications. Briefly, 30 pmol of purifed IN was incubated with various amounts of R, R(ND)-GZ-LEDGF, R-(ND)-GZ-IBD, LEDGF, or IBD for 20 min on ice. The target DNA ( DNA cleaved with HindIII, 3 g) was added to the protein mix and incubated for a further 20 min on ice. The in vitro integration reaction was started by addition of 3 pmol of the donor DNA (constructed by annealing FB64 and FB65-2; Table 1 ) and incubating the mixture for 30 min at 37°C in 25 mM KCl, 10 mM 2-mercaptoethanol, 30 mM 2-(N-morpholino)ethanesulfonic acid (MES, pH 6.7), 15 mM MnCl 2 , 10% glycerol, bovine serum albumin (BSA, 100 g/ml). The reaction was stopped by adding proteinase K (50 g/ml) and 0.5% sodium dodecyl sulfate (SDS) for 30 min at 37°C. The DNA was purified with a QIAquick PCR purification kit (Qiagen). The PCR amplification, using FB66 as a primer in the donor DNA region and radiolabeled FB182 (bottom strand) or FB183 (top strand) in a region of the DNA close to the right operator (O R ) site, was performed as described (Bushman, 1994; Diamond and Bushman, 2005) . Labeled products were resolved on a 6% denaturing polyacrylamide gel, visualized by autoradiography, and analyzed with ImageQuant 1.2 software (GE Healthcare Life Sciences).
RESULTS AND DISCUSSION
Design and purification of R-LEDGF/p75 fusions
The LEDGF/p75 protein (Fig. 1B) contains a well-defined domain near the C terminus, the IBD, that binds to HIV IN (Cherepanov et al., 2004 (Cherepanov et al., , 2005 . Fusions were constructed containing full LEDGF/p75 or the IBD (amino acids 326-530) linked to the DNA-binding domain of phage repressor [termed R(ND)] (Fig. 2) . Early studies of LEDGF/p75 suggested that it bound to DNA sequence specifically (Shinohara et al., 2002) , but more recent reports indicate that LEDGF/p75 binds to many different primary DNA sequences (Singh et al., 2006; Turlure et al., 2006) . Consistent with this latter report, we found that purified LEDGF/p75 protein bound to DNA sequence nonspecifically under the conditions used to assay HIV integration in vitro (data not shown).
One advantage of the use of R as a fusion partner is that we could monitor DNA binding early during development of our recombinant proteins, using assays of immunity to infection in E. coli (Fig. 2) (Ptashne, 1992) . Escherichia coli cells expressing R are immune to infection with cI (i.e., phages mutant in the cI gene, which encodes R). Escherichia coli cells expressing low levels of R(ND) are sensitive to cI infection because the R(ND) alone does not dimerize efficiently and consequently binds only weakly to the operators (R-binding sites) Sauer et al., 1979) . We found initially that fusions of LEDGF/p75 or the IBD to R(ND) did not confer high-level immunity, indicating that the fusions likely did not dimerize efficiently and so did not bind operator DNA tightly. We therefore modified the fusions by adding a GCN4 leucine zipper (GZ), which is known to allow tight dimerization and high-affinity DNA binding when linked to R(ND) (Hu et al., 1990) . The fusions containing all three protein domains, R(ND)-GZ-LEDGF and R(ND)-GZ-IBD, did in fact confer high-level immunity to cI infection in E. coli cells, indicating tight binding to operators. These proteins were then overexpressed in E. coli and purified (Fig. 3) . integration at target DNA sites near operators. The PCR-based method used to visualize the distribution of integration sites is outlined in Fig. 4A . Integration reactions were carried out in vitro, using duplex oligonucleotides to mimic the viral DNA ends. Phage DNA was used as the integration target, and integration was studied near the right operator (O R ), which contains three subsites, O R 1, O R 2, and O R 3, each of which binds a R dimer. After incubation of IN together with the LEDGF/p75 fusions and the reactant DNAs, the products were deproteinized and analyzed by PCR. One PCR primer bound to the viral DNA end, the other to a defined site in the target DNA near the O R . The target DNA primer was end labeled. Amplification yielded a collection of products, with the length of each amplification product reflecting the location of the initial integration event in the target DNA. The labeled integration products were then separated by electrophoresis on DNA sequencing-type gels and visualized by autoradiography. Labeled size markers were coelectrophoresed in adjacent lanes. Separate target DNA primers were used to visualize integration into the top (Fig. 4B) or bottom (Fig. 4C ) DNA strand.
R-LEDGF/p75 fusions promote integration near repressor-binding sites
We next asked whether the R(ND)-GZ-LEDGF and R(ND)-GZ-IBD
Reactions lacking the required metal cofactor yielded no detectable integration products ( Fig. 4B and C, lanes 1). Reactions containing IN without any of the fusions showed a pattern of bands indicating that most of the target DNA phosphodiesters could be used as integration acceptor sites ( Fig.  4B and C, lanes 2) . Addition of R resulted in reduced integration in the regions of the O R because of steric interference with attack by IN complexes (Bushman, 1994) , but did not affect integration elsewhere in the target DNA ( Fig. 4B and C, lanes 3). For unknown reasons, one band on the top DNA strand within O R 3 was enhanced in reactions containing R, as was seen in a previous study (Bushman, 1994) . (Fig. 4B and C, lanes 5) also resulted in protection of the O R , but in addition multiple sites in the flanking target DNA sequence were substantially increased in intensity. The increase in integration was seen on both sides of the operator on both DNA strands. Figure 5 shows a quantitative trace of integration product profiles comparing reactions containing only IN with reactions containing IN and R(ND)-GZ-IBD.
Addition of R(ND)-GZ-LEDGF (Fig. 4B and C, lanes 4) or R(ND)-GZ-IBD
As a further control, reactions were also compared with those that had been carried out in the presence of purified IBD (LEDGF/p75, residues 326-530 only). These showed integration patterns identical to that of IN alone ( Fig. 4B and C, lanes 6), indicating that tethering of the IBD near O R DNA via fusion to R(ND) is required for the local increase in integration.
Statistical analysis of targeting preferences
A statistical analysis was carried out to verify that integration was increased selectively near the O R . Control bands that did not change much in intensity in the various reactions were identified on either side of the O R on both DNA strands from the gels in Fig. 4B and C (bands marked ␤, ␦, , and ) . Bands closer to the O R that were increased in intensity in the presence of the R-LEDGF/p75 fusions were similarly identified on the same gels (bands marked ␣, ␥, , and ). The intensities of these bands were quantified by PhosphorImager (GE Healthcare Life Sciences) and the ratios of affected bands to control bands were determined. For each band analyzed, two or three independent integration reactions were used, and 10-12 gel lanes were quantified. The collection of ratios (␣/␤, ␥/␦, /, and /) was then separated into those from reactions expected to show targeting [R(ND)-GZ-LEDGF and R(ND)- GZ-IBD] and controls (IN only, or IN plus R, LEDGF/p75, or IBD) . The mean values of the two sets of ratios were then compared by nonparametric Mann-Whitney test. This showed that differences were highly significant (p Ͻ 0.0061), with selectively increased integration seen near the O R on both DNA strands and on both sides of the O R in the reactions containing R(ND)-GZ-LEDGF and R(ND)-GZ-IBD. As a precaution, we repeated the statistical test, excluding the values from the gel in Fig. 4B and C, which were used in the initial selection of bands to compare, and the differences were still found to be highly significant. Taken together, these findings indicate that the LEDGF IBD, bound at the O R via fusion to R, can direct increased integration at nearby DNA sites in vitro.
Summary and implications
Previously we reported that LEDGF/p75, a cellular IN-binding protein, is a mediator of HIV integration targeting in vivo, based on the finding that cells depleted for LEDGF/p75 showed significantly reduced integration in TUs . Here we report that tethering of LEDGF/p75-IBD to operators, using R fusions, resulted in increased integration near these sites. These results support a model in which a protein-protein interaction between LEDGF/p75 and IN helps guide integration target site selection during HIV infection. These findings open the possibility that engineered tethering interactions might be developed to constrain integration targeting. For example, it may be possible to engineer new contact sites on retroviral INs that bind to cellular proteins that are enriched on chromosomal regions where integration is benign.
